Thomas Klein
Family Medicine · Wichita, KSNPI 1528020195
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,180 of the $3,675 with a category attached, or 86.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,229 and has fallen 69.6% since, to $374 in 2023.
Across 227 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$581
- AbbVie$510
- Eli Lilly$487
- Novo Nordisk$458
- Astrazeneca UK Limited$374
- Pfizer$191
- plus $1K from 24 others
Across 347 payments — averaging $9702.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.3M
- Astrazeneca UK Limited$790K
- Pfizer$339K
- Eisai Inc.$273K
- Ironwood Pharmaceuticals, Inc$180K
- Eli Lilly$128K
- plus $379K from 6 others
What the payments were for
- Travel & lodging$48713%
- Food & beverage$3,18087%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 43 | $581 |
| AbbVie(2 entities) | 45 | $510 |
| Eli Lilly | 1 | $487 |
| Novo Nordisk | 43 | $458 |
| Astrazeneca UK Limited | 6 | $374 |
| Pfizer | 9 | $191 |
| Lilly USA, LLC | 15 | $176 |
| Sanofi-aventis U.S. LLC | 10 | $136 |
| Amarin Pharma, Inc. | 7 | $96 |
| Eisai Inc. | 6 | $85 |
| Teva Pharmaceuticals USA, Inc. | 6 | $70 |
| Abbott | 4 | $57 |
| Ironwood Pharmaceuticals, Inc | 4 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| Bayer | 2 | $39 |
| Esperion Therapeutics, Inc. | 3 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $24 |
| AstraZeneca | 2 | $23 |
| Glaukos Corporation | 1 | $19 |
| Novartis | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Apria Healthcare LLC | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Medtronic | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
| Neos Therapeutics, LP | 1 | $11 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COLOGUARD$107
How this compares
$3,675 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Mila MeansWichita$241K
- Cole GillenwaterWichita$62K
- Hai TruongWichita$25K
- Deborah OutwaterWichita$25K
- Joseph SackWichita$21K
- Scott StringfieldWichita$20K
- Mark LeikerWichita$20K
- Paul DavisWichita$18K
- Tara NeilWichita$16K
- William SimonWichita$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.